“The FDA submission for InterStim Micro and SureScan MRI leads is a significant milestone for Medtronic and a leap forward in our 20-year history of leadership in sacral neuromodulation,” in a press release said Brooke Story, vice president and general manager of the Pelvic Health & Gastric Therapies business at Medtronic. “Our ultimate goal is to provide safe and effective treatments to patients affected by bladder and bowel dysfunction, and ensure they have a choice in selecting the most appropriate therapy for their unique situation.”
Flashbacks: InterStim Incontinence and Bladder Control Implant Now Controlled via App; InterStim II System for Sacral Nerve Stimulation
Via: Medtronic
Original Article: (https://www.medgadget.com/2019/10/medtronics-tiny-new-interstim-micro-neurostimulator-submitted-to-fda.html)